M&A / Deals Cancer biotech Parabilis books record IPO, raising $670m PharmaphorumParabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.OncologyRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Alzecure enters collaboration and with Lilly for Alzheimer’s projectNext: Aditxt and Ignite announce merger plans with strategic partner Related Stories M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash pharminent June 29, 2026 M&A / Deals Ipsen charts $1.75bn course for Kartos acquisition pharminent June 29, 2026 M&A / Deals Immunai and Boehringer partner to identify T-cell targets pharminent June 26, 2026
